<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126916</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL1531</org_study_id>
    <secondary_id>NCI-2016-01734</secondary_id>
    <secondary_id>ANBL1531</secondary_id>
    <secondary_id>ANBL1531</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT03126916</nct_id>
  </id_info>
  <brief_title>Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma</brief_title>
  <official_title>A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating
      younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
      Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and
      not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy
      may work better compared to crizotinib and standard therapy alone in treating younger
      patients with neuroblastoma or ganglioneuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine in the context of a randomized trial whether the event-free survival (EFS) of
      patients with newly diagnosed high-risk neuroblastoma (NBL) is improved with the addition of
      iobenguane I-131 (131I-MIBG) during induction, prior to tandem autologous stem cell
      transplantation (ASCT).

      II. To determine whether the addition of crizotinib to intensive multimodality therapy for
      patients with high-risk NBL whose tumors harbor activating point mutations in or
      amplification of the ALK gene results in superior EFS compared to a contemporaneously treated
      cohort of patients whose tumors lack these ALK aberrations.

      SECONDARY OBJECTIVES:

      I. To describe the toxicities associated with treatment for high-risk NBL with and without
      the addition of 131I-MIBG or crizotinib.

      II. To estimate EFS and describe toxicity in patients with newly diagnosed high-risk NBL
      randomized to treatment with an 131I-MIBG-containing induction prior to busulfan/melphalan
      (BuMel) ASCT.

      III. To describe the overall survival (OS) and response rates (evaluated per International
      Neuroblastoma Response Criteria [INRC] criteria prior to ASCT and prior to post-consolidation
      therapy) for patients with high-risk neuroblastoma treated with or without 131I-MIBG or
      crizotinib.

      IV. To prospectively evaluate the relationship of response rate per revised International
      Neuroblastoma Response Criteria (INRC) to EFS and OS in patients with high-risk NBL treated
      with and without the addition of 131I-MIBG or crizotinib.

      EXPLORATORY OBJECTIVES:

      I. To evaluate whole body radiation dose, tumor factors, and host factors as potential
      predictors of efficacy and/or toxicity associated with 131I-MIBG therapy and transplant
      conditioning.

      II. To determine whether the efficacy (end-induction response, EFS, and OS) of crizotinib is
      associated with specific ALK mutations or ALK amplification.

      III. To characterize changes in tumor markers (circulating tumor deoxyribonucleic acid [DNA],
      including ALK and other tumor specific genetic aberrations, and circulating GD2) over time in
      response to protocol therapy.

      IV. To correlate results of tumor and host profiling with end-induction response and EFS.

      V. To prospectively evaluate EFS for patients with MIBG non-avid high-risk NBL compared to
      patients with MIBG-avid high-risk NBL who are randomized to treatment without 131I-MIBG.

      VI. To correlate Curie scores calculated from 131I-MIBG post-treatment scans with
      end-induction response, EFS and OS.

      VII. To describe changes in image defined risk factors (IDRFs) over the course of induction
      therapy, with correlation to surgical outcomes and local failure rates following primary
      tumor resection.

      VIII. To define patterns of failure at time of first relapse or progression in patients with
      high-risk NBL.

      IX. To determine the feasibility of prospectively monitoring adverse events using electronic
      health records.

      X. To compare local, central, and computer assisted Curie score assignment at baseline and
      during therapy in patients with MIBG-avid high-risk NBL.

      XI. To compare late toxicities (including impaired organ function and secondary tumor
      occurrence) in patients treated with 131I-MIBG or crizotinib to late toxicities in patients
      who have not received these therapies.

      XII. To determine the association between household material hardship (HMH) and clinical
      outcomes, including event free and overall survival, and 131I-MIBG receipt.

      XIII. To compare the outcomes (EFS, OS, and toxicity) of patients treated with
      post-consolidation therapy that does not contain aldesleukin to historical outcome data for
      patients treated with similar induction and consolidation regimens followed by
      post-consolidation therapy that contained aldesleukin.

      OUTLINE: Patients are randomized or assigned to 1 of 5 arms.

      All patients receive cyclophosphamide intravenously (IV) over 15-30 minutes and topotecan IV
      over 30 minutes on days 1-5 during cycle 1 of induction therapy in the absence of disease
      progression or unacceptable toxicity. Patients not assigned to an Arm by the end of cycle 1
      may receive an addition cycle of cyclophosphamide and topotecan.

      ARM A:

      INDUCTION THERAPY: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV
      over 30 minutes on days 1-5 of cycle 2 and cisplatin IV over 4 hours and etoposide IV over 2
      hours on days 1-3 of cycles 3 and 5. Patients also receive vincristine IV over 1 minute on
      day 1 and dexrazoxane IV over 5-15 minutes, doxorubicin IV over 1-15 minutes, and
      cyclophosphamide IV over 1-6 hours on days 1-2 of cycle 4 in the absence of disease
      progression or unacceptable toxicity.

      CONSOLIDATION THERAPY:

      HSCT#1: Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV
      over 1 hour on days -5 to -2 in the absence of disease progression or unacceptable toxicity.

      HSCT#2: Patients receive melphalan IV over 30 minutes on days -7 to -5, and etoposide IV over
      24 hours and carboplatin IV over 24 hours on days -7 to -4 in the absence of disease
      progression or unacceptable toxicity.

      POST-CONSOLIDATION THERAPY: Patients receive sargramostim subcutaneously (SC) on days 1-14,
      dinutuximab IV over 10 hours on days 4-7 of cycles 1-5, and isotretinoin orally (PO) twice
      daily (BID) on days 11-24 of cycles 1-5, and days 15-28 during cycle 6 in the absence of
      disease progression or unacceptable toxicity.

      ARM B:

      INDUCTION THERAPY: Patients receive cyclophosphamide, topotecan, cisplatin, and etoposide as
      in Arm A, iobenguane I-131 IV over 1.5-2 hours on day 1 beginning 3 weeks after the start of
      cycle 3, and vincristine, dexrazoxane, doxorubicin, and cyclophosphamide as in Arm A
      beginning no sooner than 35 days after the infusion of iobenguane I-131.

      CONSOLIDATION THERAPY:

      HSCT#1: Patients receive thiotepa and cyclophosphamide as in Arm A.

      HSCT#2: Patients receive melphalan, etoposide, and carboplatin as in Arm A.

      POST-CONSLIDATION THERAPY: Patients receive sargramostim, dinutuximab, and isotretinoin as in
      Arm A-D.

      ARM C:

      INDUCTION THERAPY: Patients receive cyclophosphamide, topotecan, cisplatin, etoposide,
      iobenguane I-131, vincristine, dexrazoxane, doxorubicin, and cyclophosphamide as in Arm B.

      CONSOLIDATION THERAPY: Patients receive busulfan IV over 3 hours on days -6 to -3 and
      melphalan IV over 30 minutes on day -1 in the absence of disease progression or unacceptable
      toxicity.

      POST-CONSOLIDATION THERAPY: Patients receive sargramostim, dinutuximab, and isotretinoin as
      in Arm A.

      ARM D: Patients receive treatment identical to Arm A.

      ARM E:

      INDUCTION THERAPY: Patients receive cyclophosphamide, topotecan, cisplatin, etoposide,
      vincristine, dexrazoxane, doxorubicin, and cyclophosphamide as in Arm A. Patients also
      receive crizotinib PO BID on days 1-21 of cycles 2-4 and days 1-8 of cycle 5 prior to HSCT #1
      in the absence of disease progression or unacceptable toxicity.

      CONSOLIDATION THERAPY:

      HSCT#1: Patients receive thiotepa and cyclophosphamide as in Arm A. Patients also receive
      crizotinib PO BID until day -8 of HSCT#2 in the absence of disease progression or
      unacceptable toxicity.

      HSCT#2: Patients receive melphalan, etoposide, carboplatin as in Arm A. Crizotinib is
      restarted when external beam radiation is initiated, provided there is no evidence of disease
      progression or unacceptable toxicity.

      POST-CONSOLIDATION THERAPY: Patients receive sargramostim and dinutuximab as in Arm A-D.
      Patients also receive isotretinoin PO BID on days 11-24 of cycles 1-5 and days 15-28 of cycle
      6, and crizotinib PO BID on days 1-28 of cycles 1-6 in the absence of disease progression or
      unacceptable toxicity.

      CONTINUATION THERAPY: Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28
      days for 1 year in the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients in Arms A-D are followed up every 3 months for 18
      months, and then every 6 months for 42 months; patients in Arm E are followed up every 3
      months for 6 months, and then every 6 months for 42 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS) (Arm A, B, D, and E)</measure>
    <time_frame>3 years</time_frame>
    <description>EFS time is calculated from date of randomization or assignment to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 18 months for Arms A-D and 28 months for Arm E</time_frame>
    <description>The proportion of patients with at least one Grade 3 or higher toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS (Arm C)</measure>
    <time_frame>3 years</time_frame>
    <description>EFS time is calculated from date of randomization to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>OS time is calculated from date of randomization or assignment until death, or until last contact if patient is alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The response rate will be calculated among all evaluable patients at end-Induction. Responders are defined as patients who achieve a &gt;= partial response (PR) per the revised International Neuroblastoma Response Criteria (INRC).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">813</enrollment>
  <condition>Ganglioneuroblastoma</condition>
  <condition>INRG Stage L2</condition>
  <condition>INRG Stage M</condition>
  <condition>INRG Stage MS</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Arm A in detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Arm B in detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Arm C in detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Arm D in detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Arm E in detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous HSCT</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Autologous Hematopoietic Cell Transplantation</other_name>
    <other_name>Autologous Stem Cell Transplantation</other_name>
    <other_name>Stem Cell Transplantation, Autologous</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>MET Tyrosine Kinase Inhibitor PF-02341066</other_name>
    <other_name>PF-02341066</other_name>
    <other_name>PF-2341066</other_name>
    <other_name>Xalkori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>2, 6-Piperazinedione, 4,4''-propylenedi-, (P)- (8CI)</other_name>
    <other_name>2,6-Piperazinedione, 4, 4''-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)</other_name>
    <other_name>ADR-529</other_name>
    <other_name>ICRF-187</other_name>
    <other_name>Razoxane (+)-form</other_name>
    <other_name>Soluble ICRF (L-isomer)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Cardioxane</other_name>
    <other_name>Totect</other_name>
    <other_name>Zinecard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dinutuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Ch 14.18UTC</other_name>
    <other_name>Ch14.18</other_name>
    <other_name>MOAB Ch14.18</other_name>
    <other_name>monoclonal antibody Ch14.18</other_name>
    <other_name>Unituxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin HCl</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Etopophos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo EBRT</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiation</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
    <other_name>Radiation, External Beam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Iobenguane I-131</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <other_name>(131)I-MIBG</other_name>
    <other_name>131I-MIBG</other_name>
    <other_name>I 131 Meta-iodobenzylguanidine</other_name>
    <other_name>I-131 Metaiodobenzylguanidine</other_name>
    <other_name>Iobenguane (131I)</other_name>
    <other_name>Iobenguane I 131</other_name>
    <other_name>iodine I 131 metaiodobenzylguanidine</other_name>
    <other_name>MIBG I-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>13-cis retinoic acid</other_name>
    <other_name>13-cis-Retinoate</other_name>
    <other_name>13-cis-Retinoic Acid</other_name>
    <other_name>13-cis-Vitamin A Acid</other_name>
    <other_name>13-cRA</other_name>
    <other_name>Absorica</other_name>
    <other_name>Accure</other_name>
    <other_name>Accutane</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>cis-Retinoic Acid</other_name>
    <other_name>Cistane</other_name>
    <other_name>Claravis</other_name>
    <other_name>Isotretinoinum</other_name>
    <other_name>Isotrex</other_name>
    <other_name>Isotrexin</other_name>
    <other_name>Myorisan</other_name>
    <other_name>Neovitamin A</other_name>
    <other_name>Neovitamin A Acid</other_name>
    <other_name>Oratane</other_name>
    <other_name>Retinoicacid-13-cis</other_name>
    <other_name>Ro 4-3780</other_name>
    <other_name>Ro-4-3780</other_name>
    <other_name>Roaccutan</other_name>
    <other_name>Roaccutane</other_name>
    <other_name>Roacutan</other_name>
    <other_name>Sotret</other_name>
    <other_name>ZENATANE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>Alkerana</other_name>
    <other_name>Evomela</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo standard of care surgery</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Topotecan Lactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm E (crizotinib, chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Leurocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)</arm_group_label>
    <arm_group_label>Arm D (chemotherapy, HSCT, EBRT)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be enrolled on ANBL00B1 or APEC14B1 prior to enrollment on ANBL1531

          -  Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular)
             verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone
             marrow with elevated urinary catecholamine metabolites; the following disease groups
             are eligible:

               -  Patients with International Neuroblastoma Risk Group (INRG) stage M disease are
                  eligible if found to have either of the following features:

                    -  MYCN amplification (&gt; 4-fold increase in MYCN signals as compared to
                       reference signals), regardless of additional biologic features; OR

                    -  Age &gt; 547 days regardless of biologic features

               -  Patients with INRG stage MS disease with MYCN amplification

               -  Patients with INRG stage L2 disease with MYCN amplification

               -  Patients &gt; 547 days of age initially diagnosed with INRG stage L1, L2 or MS
                  disease who progressed to stage M without prior chemotherapy may enroll within 4
                  weeks of progression to stage M

               -  Patients &gt;= 365 days of age initially diagnosed with MYCN amplified INRG stage L1
                  disease who progress to stage M without systemic therapy may enroll within 4
                  weeks of progression to stage M

          -  Patients initially recognized to have high-risk disease must have had no prior
             systemic therapy (other than topotecan/cyclophosphamide initiated on an emergent basis
             and within allowed timing); patients observed or treated with a single cycle of
             chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per
             ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high risk disease
             but subsequently found to meet the criteria will also be eligible; patients who
             receive localized emergency radiation to sites of life-threatening or
             function-threatening disease prior to or immediately after establishment of the
             definitive diagnosis will be eligible

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows:

               -  1 to &lt; 2 years: male = 0.6; female = 0.6

               -  2 to &lt; 6 years: male = 0.8; female = 0.8

               -  6 to &lt; 10 years: male = 1; female = 1

               -  10 to &lt; 13 years: male = 1.2; female = 1.2

               -  13 to &lt; 16 years: male = 1.5; female = 1.4

               -  &gt;= 16 years: male = 1.7; female = 1.4

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) for age, and

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &lt; 10 x
             ULN; for the purposes of this study, ULN for SGPT (ALT) is 45

          -  Shortening fraction of &gt;= 27% by echocardiogram, or ejection fraction of &gt; 50% by
             echocardiogram or radionuclide angiogram

          -  No known contraindication to peripheral blood stem cell (PBSC) collection; examples of
             contraindications might be a weight or size less than the collecting institution finds
             feasible, or a physical condition that would limit the ability of the child to undergo
             apheresis catheter placement (if necessary) and/or the apheresis procedure

        Exclusion Criteria:

          -  Patients with INRG stage L2 tumors without amplification of MYCN regardless of tumor
             histology (may meet criteria for high risk classification but are not eligible for
             this trial)

          -  Patients with bone marrow failure syndromes

          -  Patients for whom targeted radiopharmaceutical therapy would be contraindicated due to
             underlying medical disorders

          -  Female patients who are pregnant since fetal toxicities and teratogenic effects have
             been noted for several of the study drugs; a pregnancy test is required for female
             patients of childbearing potential

          -  Lactating females who plan to breastfeed their infants

          -  Sexually active patients of reproductive potential who have not agreed to use an
             effective contraceptive method for the duration of their study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>365 Days</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven DuBois</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>205-638-9285</phone>
      <email>oncologyresearch@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew A. Kutny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>602-546-0920</phone>
    </contact>
    <investigator>
      <last_name>Jessica Boklan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>501-364-7373</phone>
    </contact>
    <investigator>
      <last_name>David L. Becton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Downey Medical Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Robert M. Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>909-558-3375</phone>
    </contact>
    <investigator>
      <last_name>Albert Kheradpour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>323-361-4110</phone>
    </contact>
    <investigator>
      <last_name>Leo Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>310-825-6708</phone>
    </contact>
    <investigator>
      <last_name>William A. May</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Children's Hospital</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>559-353-3000</phone>
      <email>Research@valleychildrens.org</email>
    </contact>
    <investigator>
      <last_name>Vonda L. Crouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Laura A. Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>714-997-3000</phone>
    </contact>
    <investigator>
      <last_name>Elyssa M. Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-694-0012</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jay Michael S. Balagtas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Marcio H. Malogolowkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>858-966-5934</phone>
    </contact>
    <investigator>
      <last_name>William D. Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center -San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>619-532-8712</phone>
    </contact>
    <investigator>
      <last_name>Yoko T. Udaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Kieuhoa T. Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>303-764-5056</phone>
      <email>josh.b.gordon@nsmtp.kp.org</email>
    </contact>
    <investigator>
      <last_name>Margaret E. Macy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>303-839-6000</phone>
    </contact>
    <investigator>
      <last_name>Jennifer J. Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>860-545-9981</phone>
    </contact>
    <investigator>
      <last_name>Michael S. Isakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Nina S. Kadan-Lottick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>302-651-6884</phone>
      <email>dperry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>202-884-2549</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey S. Dome</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>239-343-5333</phone>
      <email>molly.arnstrom@leehealth.org</email>
    </contact>
    <investigator>
      <last_name>Emad K. Salman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>352-273-8010</phone>
      <email>cancer-center@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>William B. Slayton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>954-265-1847</phone>
      <email>OHR@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Iftikhar Hanif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>904-697-3529</phone>
    </contact>
    <investigator>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Julio C. Barredo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-624-2778</phone>
    </contact>
    <investigator>
      <last_name>Enrique A. Escalon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>407-303-2090</phone>
      <email>FH.Cancer.Research@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Fouad M. Hajjar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>407-650-7150</phone>
    </contact>
    <investigator>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>727-767-4784</phone>
      <email>Ashley.Repp@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan L. Metts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>561-881-2815</phone>
    </contact>
    <investigator>
      <last_name>Narayana Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>404-785-2025</phone>
      <email>Leann.Schilling@choa.org</email>
    </contact>
    <investigator>
      <last_name>William T. Cash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>912-350-7887</phone>
      <email>clayter1@memorialhealth.com</email>
    </contact>
    <investigator>
      <last_name>Andrew L. Pendleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-983-6090</phone>
    </contact>
    <investigator>
      <last_name>Wade T. Kyono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-880-4562</phone>
    </contact>
    <investigator>
      <last_name>Jennifer L. Reichek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>312-355-3046</phone>
    </contact>
    <investigator>
      <last_name>Mary L. Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Susan L. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>847-723-7570</phone>
    </contact>
    <investigator>
      <last_name>Rebecca E. McFall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Park Ridge</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca E. McFall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-226-4343</phone>
    </contact>
    <investigator>
      <last_name>Jaime M. Libes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-545-7929</phone>
    </contact>
    <investigator>
      <last_name>Gregory P. Brandt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-248-1199</phone>
    </contact>
    <investigator>
      <last_name>Sandeep Batra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-241-8912</phone>
      <email>samantha.mallory@unitypoint.org</email>
    </contact>
    <investigator>
      <last_name>Samantha L. Mallory</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>Mariko Sato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>James T. Badgett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>CHResearch@lcmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Lolie C. Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>207-973-4274</phone>
    </contact>
    <investigator>
      <last_name>Nadine P. SantaCruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>207-396-7581</phone>
      <email>sverwys@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Eric C. Larsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>410-601-6120</phone>
      <email>pridgely@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Jason M. Fixler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Allen R. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-726-5130</phone>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Rajen Mody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Roland L. Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Saint John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Adonis N. Lorenzana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Children's Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>248-551-7695</phone>
    </contact>
    <investigator>
      <last_name>Laura K. Gowans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>612-813-5193</phone>
    </contact>
    <investigator>
      <last_name>Michael K. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>612-624-2620</phone>
    </contact>
    <investigator>
      <last_name>Emily G. Greengard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Carola A. Arndt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>601-815-6700</phone>
    </contact>
    <investigator>
      <last_name>Anderson (Andy) B. Collier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Regional</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Barbara A. Gruner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>816-302-6808</phone>
      <email>rryan@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Keith J. August</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-251-7066</phone>
    </contact>
    <investigator>
      <last_name>Robin D. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>402-955-3949</phone>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>402-559-6941</phone>
      <email>unmcrsa@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Childhood Diseases/Cure 4 the Kids Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summerlin Hospital Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>201-996-2879</phone>
    </contact>
    <investigator>
      <last_name>Burton E. Appel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>973-971-5900</phone>
    </contact>
    <investigator>
      <last_name>John J. Gregory</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>973-754-2207</phone>
      <email>HallL@sjhmc.org</email>
    </contact>
    <investigator>
      <last_name>Alissa Kahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>518-262-5513</phone>
    </contact>
    <investigator>
      <last_name>Lauren R. Weintraub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>718-765-2500</phone>
    </contact>
    <investigator>
      <last_name>Mahmut Y. Celiker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Clare J. Twist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>516-663-3115</phone>
    </contact>
    <investigator>
      <last_name>Mark E. Weinblatt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-263-4434</phone>
      <email>prmc.coordinator@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sharon L. Gardner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-305-6361</phone>
      <email>nr2616@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Alice Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Angela R. Girvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>914-594-3794</phone>
    </contact>
    <investigator>
      <last_name>Jessica C. Hochberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>828-418-1354</phone>
      <email>courtney.trafford@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Douglas J. Scothorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-668-0683</phone>
      <email>cancerclinicaltrials@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart H. Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-804-9376</phone>
    </contact>
    <investigator>
      <last_name>Joel A. Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-275-3853</phone>
    </contact>
    <investigator>
      <last_name>Jessica M. Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>252-744-1015</phone>
      <email>eubankss@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea R. Whitfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <investigator>
      <last_name>David E. Kram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>513-636-2799</phone>
      <email>cancer@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian D. Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>216-844-5437</phone>
    </contact>
    <investigator>
      <last_name>Duncan S. Stearns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-223-8100</phone>
      <email>CancerAnswer@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Rabi Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>614-072-2657</phone>
      <email>amy.yekisa@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mark A. Ranalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-228-4055</phone>
    </contact>
    <investigator>
      <last_name>Ayman A. El-Sheikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jamie L. Dargart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>503-413-2560</phone>
    </contact>
    <investigator>
      <last_name>Janice F. Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital-Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Felipe S. Bautista-Otanez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>570-271-5251</phone>
      <email>HemonCCTrials@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Jagadeesh Ramdas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>717-531-6012</phone>
    </contact>
    <investigator>
      <last_name>Lisa M. McGregor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>267-425-5544</phone>
      <email>CancerTrials@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Rochelle Bagatell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-692-8570</phone>
      <email>jean.tersak@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Jean M. Tersak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>401-444-1488</phone>
    </contact>
    <investigator>
      <last_name>Jennifer J. Greene Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>843-792-9321</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline M. Kraveka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Richland Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>803-434-3533</phone>
    </contact>
    <investigator>
      <last_name>Stuart L. Cramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Nichole L. Bryant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>605-312-3320</phone>
      <email>OncologyClinicalTrialsSF@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Kayelyn J. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>865-541-8266</phone>
    </contact>
    <investigator>
      <last_name>Ray C. Pais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Daniel J. Benedetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>512-628-1902</phone>
      <email>TXAUS-DL-SFCHemonc.research@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Shannon M. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>361-694-5311</phone>
      <email>Crystal.DeLosSantos@dchstx.org</email>
    </contact>
    <investigator>
      <last_name>Nkechi I. Mba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>972-566-5588</phone>
    </contact>
    <investigator>
      <last_name>Stanton C. Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>214-648-7097</phone>
      <email>canceranswerline@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya C. Watt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>682-885-2103</phone>
      <email>CookChildrensResearch@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mary Meaghan P. Granger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer H. Foster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Kishor M. Bhende</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Timothy C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>210-575-6240</phone>
      <email>Vinod.GidvaniDiaz@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Vinod K. Gidvani-Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>210-450-3800</phone>
      <email>phoresearchoffice@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie R. Langevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>801-585-5270</phone>
    </contact>
    <investigator>
      <last_name>Phillip E. Barnette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont and State Agricultural College</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>802-656-8990</phone>
      <email>rpo@uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica L. Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>804-628-1914</phone>
      <email>klcampbell@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Madhu S. Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-987-2000</phone>
    </contact>
    <investigator>
      <last_name>Douglas S. Hawkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-228-6618</phone>
      <email>HopeBeginsHere@providence.org</email>
    </contact>
    <investigator>
      <last_name>Judy L. Felgenhauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>253-968-0129</phone>
      <email>mamcdci@amedd.army.mil</email>
    </contact>
    <investigator>
      <last_name>Melissa A. Forouhar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>304-293-7374</phone>
      <email>cancertrialsinfo@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephan R. Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Kenneth B. De Santes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Center-Marshfield</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-782-8581</phone>
      <email>oncology.clinical.trials@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michelle A. Manalang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-955-4727</phone>
      <email>MACCCTO@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Meghen B. Browning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>604-875-2345</phone>
      <phone_ext>6477</phone_ext>
    </contact>
    <investigator>
      <last_name>David B. Dix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-561-1026</phone>
      <email>ctu_web@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Tanya R. Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Janeway Child Health Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-722-1126</phone>
    </contact>
    <investigator>
      <last_name>Lisa A. Goodyear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>902-470-6767</phone>
    </contact>
    <investigator>
      <last_name>Conrad V. Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>519-685-8306</phone>
    </contact>
    <investigator>
      <last_name>Shayna M. Zelcer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>613-738-3931</phone>
    </contact>
    <investigator>
      <last_name>Donna L. Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>2027</phone_ext>
      <email>jason.mcguire@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel A. Morgenstern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIMA San Pablo Oncologic Hospital</name>
      <address>
        <city>Caguas</city>
        <zip>00726</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>787-653-3434</phone>
    </contact>
    <investigator>
      <last_name>Jhon A. Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Ganglioneuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
    <mesh_term>Ch14.18 monoclonal antibody</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

